Pharma BD Deal Intelligence

GSK plc / CAMP4 Therapeutics Corporation

2025 · Licensing/Option · Complete

CAMP4 Therapeutics and GSK entered a research, collaboration and license agreement dated 17 December 2025 (announced 18 December 2025) to discover and develop antisense oligonucleotide therapeutics targeting regulatory RNAs across multiple gene targets in neurodegenerative and kidney disease. CAMP4 applies its RAP Platform to identify regRNAs and generate ASO candidates that upregulate target gene expression; GSK is responsible for subsequent development and commercialization. CAMP4 receives a USD 17.5 million cash upfront plus undisclosed development and commercial milestones and tiered royalties.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  GSK plc deals